{
    "organizations": [],
    "uuid": "3bf5b21d30a9e179f0ed374febde60189fffacd4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-exact-sciences-q4-loss-per-share-0/brief-exact-sciences-q4-loss-per-share-0-18-idUSASB0C74D",
    "ord_in_thread": 0,
    "title": "BRIEF-Exact Sciences Q4 Loss Per Share $0.18",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - Exact Sciences Corp:\n* COLOGUARDÂ® REVENUE INCREASED 168 PERCENT TO $266 MILLION * Q4 LOSS PER SHARE $0.18 * Q4 REVENUE ROSE 148 PERCENT TO $87.4 MILLION * SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION * ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.\n* Q4 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $85.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-23T05:32:00.000+02:00",
    "crawled": "2018-02-23T15:49:00.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "exact",
        "science",
        "corp",
        "revenue",
        "increased",
        "percent",
        "million",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "revenue",
        "rose",
        "percent",
        "million",
        "see",
        "fy",
        "revenue",
        "million",
        "million",
        "anticipates",
        "completed",
        "cologuard",
        "test",
        "volume",
        "test",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}